approv treatment r/r make pemazyr
pemigatinib first approv target therapi cca drug approv base
studi discuss larg anticip given clear
improv rel soc orr month mpf month os price
per cours expect cours per patient averag believ
repres opportun could expand success
develop fgfr-alter malign address patient includ
patient patient via tumor agnost
approach follow page also provid overview ruxcovid trial
patient sever final given expect tafasitamab launch later
year take opportun add product model result
new price target
label efficaci data base updat data esmo
provid updat demonstr orr
pr diseas control rate mpf month
preliminari mo month note note durat respons
label improv month month longer month report
esmo respond achiev durat respons month greater
label safeti data includ precaut around hypophosphatemia ocular
signal esmo find safeti analysi larg in-
line prior updat common grade ae hypophosphatemia
grade higher retin detatch observ patient
safeti data label includ larger safeti popul
found retin detach patient grade higher
case dose reduct led symptom resolut result discontinu
patient note warn label retin detach
hyperphosphatemia embryo-fet toxic also balversa label bladder
fraction futur pemazyr opportun though
rel small indic patient global estimate peak
sale data provid posit read-through fgfr-alter malign
patient total current evalu pemazyr
bladder continu dose cohort data expect ye/earli
trial enrol tumor-agnost trial activ
brief overview trial provid next page
commerci clinic risk jakafi/ruxo olumi pemi capmatinib topic rux
leader develop drug oncolog dermatolog
dcf includ follow
pemazyr sale cholangio tafasitamab sale
r/r dlbcl topic rux sale atop derm
vitiligo european iclusig sale global
olumi royalti capmatinib royalti
debt total capit
piper sandler seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
ruxolitinib evalu treatment cytokin storm patient
ruxcovid global random placebo-control phase studi evalu
safeti efficaci ruxolitinib patient cytokin storm caus
hypothes sever attenu jak-stat pathway inhibit
therefor highlight potenti ruxolitinib inhibitor treat patient
primari endpoint proport patient die develop respiratori failur requir
ventil requir icu admiss day secondari endpoint includ evalu
ventil requir durat hospit icu stay supplement oxygen invas
mechan ventil chang nation earli warn score chang
ratio proport patient oxygen therapi oxygen satur
room air safeti manag believ ruxolitinib dose bid potenti
ideal dose enough decreas cytokin level impair jak-stat
signal enough disrupt viral respons alongsid trial also initi
expand access program us patient sever receiv
ruxolitinib outsid ruxcovid trial
tafasitamab addit model increas price target per share
follow acquisit right sign co-commerci deal
morphysi mor brill earlier year discuss final ad tafasitamab
model estim us launch later year bla submit decemb
eu launch next year submiss expect r/r dlbcl model us
ex-u sale approach respect per agreement
compani co-commerci tafasitamab us profit/loss share
gain full ex-u right pay morphosi royalti net sale morphosi
elig receiv mileston tier royalti ex-u sale tafasitamab
mid-teen mid-twenti rang
page
cca patient
cca patient
a/m/u icca patient
refractori a/m/u cca patient fusion
page
nhl patient
dlbcl patient
r/r dlbcl patient
r/r dlbcl patient elig transplant
page
us japan regulatori file
data brave brave ii phase trial
data phase ii continu dose cohort
r/r dlbcl combo lenalidomid
r/r dlbcl combo lenalidomid
nsclc exon mutat
current disclosur inform compani locat http //www pipersandl com/researchdisclosur
page
product sale
product sale
product sale
product sale
product sale
total revenu
royalti revenu
royalti revenu
royalti revenu
total revenu
good sold
revenu
revenu
revenu
expens relat note convers
revenu
current disclosur inform compani locat http //www pipersandl com/researchdisclosur
page
good sold
revenu
revenu
revenu
current disclosur inform compani locat http //www pipersandl com/researchdisclosur
